New arm (Cohort 4) initiated in SCOPE Ph 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
Phil L’Huillier, Chief Executive Officer of Scancell, said: “We are making strong clinical and strategic progress across our portfolio. The continued momentum in the SCOPE study highlights the clinical potential of SCIB1, and the next generation iSCIB1+, to address the unmet needs in melanoma. Modi-1 continues on track for further data readouts in the year. We are also progressing plans on our commitment to unlock the full potential of our innovative GlyMab® platform by establishing Glymab Therapeutics Ltd. We are looking to bring focus to our product development execution across the portfolio while positioning ourselves to deliver future value through creating strategic optionality in a time of market headwinds.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data